$DWTX News

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial

Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track

Dogwood Therapeutics Q1 EPS $(0.15), Inline

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2

Dogwood Therapeutics Announces FDA Acceptance Of IND Application For Development Candidate SP16, Administered IV, For Treatment Of Chemotherapy-Induced Pain And Peripheral Neuropathy

Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

DWTX: Financing Secures Funding Through Phase 2b Data Readout

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Dogwood Therapeutics Announces Financing For Up TO ~$26.8M Through Registered Direct Offering And Concurrent Private Placement For Issuance Of 4,386,037 Shares And Warrants At Combined Price Of $2.85

Dogwood Therapeutics Announces Financing For Up TO ~$26.8M Through Registered Direct Offering And Concurrent Private Placement For Issuance Of 4,386,037 Shares And Warrants At Combined Price Of $2.85

DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron